Disclosed is the use of a compound of formula I wherein X is O, S, SO or SO2； R1 is halogen, trihalomethyl, -OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, -CH2-OH, -CH2-CH2-OH, C1-4alkylthio, C1-4alkylsulfinyl, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC1-4alkyl or phenyl-C1-4alkoxy each phenyl group thereof being optionally substituted by halogen, CF3, C1-4alkyl or C1-4alkoxy； R2 is H, halogen, trihalomethyl, C1-4alkoxy, C1-7alkyl, phenethyl or benzyloxy； R3 H, halogen, CF3, OH, C1-7alkyl, C1-4alkoxy, benzyloxy, phenyl or C1-4alkoxymethyl； each of R4 and R5, independently is H or a residue of formula (a) wherein each of R8 and R9, independently, is H or C1-4alkyl optionally substituted by halogen； and n is an integer from 1 to 4； or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof； or a compound of formula II wherein R1a is halogen, trihalomethyl, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, C1-4alkylsulifinyl, C1-4alkylsulfonyl, aralkyl, optionally substituted phenoxy or aralkyloxy； R2a is H, halogen, trihalomethyl, C1-4halkyl, C1-4alkoxy, aralkyl or aralkyloxy； R3a is H, halogen, CF3, C1-4alkyl, C1-4alkoxy, C1-4alkylthio or benzyloxy； R4a is H, C1-4alkyl, phenyl, optionally substituted benzyl or benzoyl, or lower aliphatic C1-5acyl； R5a is H, monohalomethyl, C1-4alkyl, C1-4alkoxy-methyl, C1-4alkyl-thiomethyl, hydroxyethyl, hydroxypropyl, phenyl, aralkyl, C2-4alkenyl or -alkynyl； R6a is H or C1-4alkyl； R7a is H, C1-4alkyl or a residue of formula (a) as defined above, Xa is O, S, SO or SO2； and na is an integer of 1 to 4； or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof； in the manufacture of a medicament for the treatment or prophylaxis of scLE and related autoimmune cutaneous conditions.
